Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07HSU
|
|||
Former ID |
DNC002327
|
|||
Drug Name |
ISIS 109524
|
|||
Drug Type |
Antisense drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Company |
Isis Pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | RANK messenger RNA (RANK mRNA) | Target Info | . | [1] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
NF-kappa B signaling pathway | ||||
Osteoclast differentiation | ||||
Prolactin signaling pathway | ||||
Rheumatoid arthritis | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
RANKL Signaling Pathway | ||||
Reactome | TNFR2 non-canonical NF-kB pathway | |||
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
WikiPathways | RANKL/RANK Signaling Pathway | |||
Osteoclast Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | US patent application no. 6,171,860, Antisense inhibition of rank expression. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.